Neutrolis's NET-Degrading Therapy: A New Dawn for Severe Lupus Patients

CAMBRIDGE, Mass. – July 15, 2026 – For professionals tracking the intersection of biotechnology and long-term market opportunity, a report published today in The New England Journal of Medicine is required reading. It details not just a scientific advance, but a potential paradigm shift in how we approach autoimmune disease. Cambridge-based Neutrolis, Inc. has provided the first clinical evidence that directly dismantling a key driver of inflammation can produce stunningly rapid results in a patient with severe, treatment-refractory Systemic Lupus Erythematosus (SLE).

This is more than another incremental step. The study documents the case of a 16.5-year-old whose body, due to a rare genetic defect, cannot produce a critical enzyme needed to clean up inflammatory cellular debris. After a lifetime of battling a cascade of debilitating symptoms and exhausting conventional therapies, a single infusion of Neutrolis's investigational drug, NTR-441, resolved key clinical symptoms within six hours. This result offers a powerful proof-of-concept for a technology that, after two decades of foundational research, may finally be ready to move from the lab to the clinic, offering a targeted weapon in a field long dominated by the blunt instruments of broad immunosuppression.

A Precision Strike in a War of Attrition

To grasp the significance of this development, one must first understand the brutal war of attrition that patients with severe SLE endure. The patient in the study, whose disease began at just 18 months old, suffered from a laundry list of afflictions: a persistent vasculitic rash over most of his body, polyarthritis, episcleritis, and inflammatory bowel disease. His condition was caused by a confirmed homozygous loss-of-function variant in the DNASE1L3 gene, meaning his immune system lacked the primary enzyme responsible for clearing away pathological DNA scaffolds known as neutrophil extracellular traps (NETs).

Conventional treatments, which aim to suppress the entire immune system, had failed to provide sustained remission. Neutrolis’s approach was fundamentally different. NTR-441 is an engineered analog of the very DNASE1L3 enzyme the patient was missing. The strategy wasn't to silence the immune system, but to restore a critical housekeeping function: enzymatically degrading the NETs that were fueling the fire.

The results were immediate and profound. Within hours of the first infusion, clinical symptoms began to resolve. Over a four-week period, the patient’s vasculitic rash coverage plummeted from 76% to 20% of his body surface area, while joint inflammation and episcleritis disappeared. Disease activity scores, along with patient, parent, and physician assessments, all showed marked improvement.

“Patients with DNASE1L3 deficiency can experience severe, early-onset autoimmune disease with limited treatment options,” said Dr. Andreas Reiff, Chief Medical Officer of Neutrolis and an author on the publication. “The speed and extent of improvement for this patient after NTR-441 treatment are an important proof-of-concept for how NET-degrading therapy can benefit patients across autoimmune and inflammatory indications.”

The Hidden Architecture of Autoimmunity

This clinical success is built on a scientific journey spanning two decades. The key culprits, NETs, are web-like structures of DNA and proteins that neutrophils - the immune system's first responders - release to trap pathogens. While essential for fighting infection, their overproduction or improper clearance is now understood to be a primary driver of tissue damage and chronic inflammation in diseases like lupus and rheumatoid arthritis. These sticky DNA webs act as persistent autoantigens, triggering a vicious cycle of immune activation.

The body's natural defense against this is DNASE1L3, an enzyme that acts like a molecular pair of scissors, dismantling NETs before they can cause harm. The Neutrolis publication provides compelling evidence linking the restoration of this function directly to clinical improvement. Biomarker data showed that as NTR-441 entered the patient's system, levels of circulating DNA fragments and myeloperoxidase-DNA complexes - the molecular footprints of NET degradation - rose sharply, correlating tightly with the patient’s recovery.

“The pharmacodynamic biomarker data in this publication confirm that restoring DNASE1L3 activity degrades NETs as designed,” stated Dr. Tobias A. Fuchs, Co-Founder and Chief Scientific Officer of Neutrolis. “The tight temporal link between NET degradation and clinical response supports our strategy of targeting NETs as a non-immunosuppressive approach.”

This validates what Dr. Abdul Hakkim, the company's Co-Founder and COO, called a “turning point built on twenty years of foundational NET biology.” It transforms the understanding of NETs from a scientific curiosity into a druggable target with profound therapeutic potential.

Clinical Realities and the Path Forward

Providing a balanced view requires acknowledging the challenges. This breakthrough is based on a single compassionate-use case, a context that demands caution when extrapolating to broader populations. Furthermore, the treatment was not without complications. During the fifth infusion, the patient developed an infusion reaction and anti-drug antibodies. This is a known risk in enzyme replacement therapy, particularly in a patient whose body has never been exposed to the native protein. The clinical team managed the reaction with a desensitization protocol, but the treatment was ultimately discontinued after the eighth infusion.

This “hidden cost” underscores the complexities of translating a brilliant scientific concept into a safe, durable therapy. It is a critical data point that Neutrolis is already addressing with its next-generation asset, NTR-1011. This improved DNASE1L3 fusion protein, designed for better stability and subcutaneous delivery, has already completed a Phase 1a study showing favorable safety and tolerability.

From Proof-of-Concept to Market Disruption

With this pivotal NEJM publication, Neutrolis has validated its core scientific thesis. The focus now shifts to execution and expansion. The company is advancing NTR-1011 into a Phase 1b study (LIBERATE-I) in patients with more common forms of SLE and rheumatoid arthritis (RA). This is the crucial next step to see if the dramatic results in a genetically defined patient can be replicated in a broader autoimmune population where NETs are also implicated, but the underlying cause is more complex.

“This publication is a defining moment for Neutrolis,” said Anthony Aiudi, the company's Chief Executive Officer. “It validates the scientific thesis our platform was built on, and it strengthens our conviction as we advance NTR-1011 into broader patient populations with SLE and RA.”

The company has strategically bolstered its leadership, notably adding former Pfizer R&D head Dr. Mikael Dolsten to its board, signaling a clear intent to navigate the path to commercialization. In a multi-billion-dollar autoimmune market crowded with immunosuppressants and other biologics, Neutrolis is positioning its exDNASE™ platform not as another 'me-too' drug, but as a fundamentally new class of therapy. By aiming to remove the root cause of inflammation rather than just managing its downstream effects, the company is making a bold play to redefine the standard of care for some of our most intractable chronic diseases.

Editor’s Note (July 17, 2026): A previous version of this article incorrectly referred to the patient in the NEJM study using female pronouns. The text has been updated to accurately reflect that the patient was a 16.5-year-old boy.